This is a Phase 2, open-label, multicenter, multiple subcutaneous injection, safety and efficacy study of PF-06835375 in adult participants with primary immune thrombocytopenia (ITP). This …

2024年1月1日 · Immune thrombocytopenia (ITP) is a rare autoimmune condition, due to peripheral platelet destruction through antibody-dependent cellular phagocytosis, complement …

特发性血小板减少性紫癜 （英語： Idiopathic thrombocytopenic purpura，ITP）是因 血小板 免疫性破坏，导致 外周血 中血小板减少的出血性 疾病。 是最常见的 血小板减少性紫癜，它是一 …

This study is designed to clarify the effects of the CXCR5 inhibitor, PF-06835375 on platelet counts in participants with moderate-to-severe primary Immune Thrombocytopenia (ITP). The …

This study is designed to clarify the effects of the CXCR5 inhibitor, PF-06835375 on platelet counts in participants with moderate-to-severe primary Immune Thrombocytopenia (ITP). …

Pfizer is conducting a phase 2 multicenter study to look at the safety and efficacy of using a drug called PF-06835375 for treatment of adults (between 18-70 years) with persistent or chronic …

2021年9月27日 · 这是 PF-06835375 在患有原发性免疫性血小板减少症 (ITP) 的成年参与者中进行的一项 2 期、开放标签、单组、多中心、多次皮下注射、安全性和有效性研究。

2021年9月27日 · This is a Phase 2, open-label, multicenter, multiple subcutaneous injection, safety and efficacy study of PF-06835375 in adult participants with primary immune …

We evaluated the value of immature platelet fraction (IPF) in differentiating immune thrombocytopenia (ITP) from thrombocytopenia secondary to bone marrow failure and its …

The age-adjusted prevalence of immune thrombocytopenic purpura (ITP) is estimated to be 9.5 per 100,000 persons in the USA while its annual incidence is estimated to be 2.68 per 100,000 …